Tonix Pharmaceuticals Holding Corp. (TNXP)

NASDAQ: TNXP · USD

$5.35

-0.04 (-0.7%)· Recorded snapshot

Market cap	91.8M
Revenue (ttm)	29.1M
Net income (ttm)	-159.7M
EPS (ttm)	-$12.5
Shares out	17.2M
Volume	487,894
Beta	1.79

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 29.1M
Net income (ttm): -159.7M
EPS (ttm): -$12.5
Market cap: 91.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-81.8

P25 -113.8P50 -46.5P75 -0.9

ROIC-52.7

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All TNXP indicators

Market & fundamental data

Available fields

200

Groups with data

Currency

USD

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001430306
Company name	Tonix Pharmaceuticals Holding Corp.
Country	United States
Country code	US
CUSIP number	890260839
Earnings date	2026-11-09
Earnings time	bmo
Employees	142
Employees change	61
Employees growth	75.31%
Enterprise value	$-83.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2007
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US8902608392
Last 10-K release date	2026-03-12
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split date	2025-02-05
Last stock split type	Reverse
Market cap	$91.8M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$5.35
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TNXP
U.S. state	New Jersey
Website	https://www.tonixpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-233.42%
FCF / EV yield	191.61%
FCF yield	-171.03%
Forward P/S	1.12x
P/B ratio	0.41x
P/S ratio	3.18x
Price / tangible book value	0.42x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	83.83%
Operating margin	-568.43%
Pretax margin	-548.64%
Profit per employee	$-1.1M
Revenue per employee	$204,944
ROA	-46.84%
ROA (5Y)	-33.86%
ROCE	-74.08%
ROE	-81.82%
ROE (5Y)	-71.44%
ROIC	-52.74%
SBC / revenue	27.28%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	10
Gross profit growth	747.67%
Net income growth years	1
Revenue growth	196.02%
Revenue growth (Q)	577.88%
Revenue growth (QoQ)	96.92%
Revenue growth quarters	4
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-5.1M
Depreciation and amortization	$2.1M
EBIT	$-165.4M
EBITDA	$-163.3M
EPS	$-12.49
FCF per share	$-9.22
Financing cash flow	$207.7M
Free cash flow	$-158.1M
Free cash flow minus SBC	$-166M
Gross profit	$24.4M
Investing cash flow	$-4.3M
Net cash flow	$50.4M
Net income	$-159.7M
Operating cash flow minus SBC	$-160.9M
Operating income	$-165.4M
Revenue	$29.1M
Stock-based compensation	$7.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-2.1
Book value per share	$13.24
Debt / equity	0.01
Interest coverage	-1,858.71
Long-term assets	$50.7M
Long-term liabilities	$1M
Net cash (debt)	$175M
Net cash / market cap	189.26%
Net cash growth	40.15%
Net debt / equity	-0.79
Piotroski F-Score	3
Property, plant and equipment	$46.1M
Shareholders' equity	$222.3M
Tangible book value	$222.2M
Tangible book value per share	$13.23
Total assets	$254.1M
Total cash	$176.2M
Total debt	$1.3M
Total liabilities	$31.8M
WACC	13.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.13
Current assets	$203.4M
Current liabilities	$30.8M
Current ratio	6.61
Inventory turnover	0.81
Net working capital	$-3.3M
Quick ratio	6.12
Working capital	$172.6M
Working capital turnover	0.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-216.89%
Dividend yield	0%
Shareholder yield	-216.89%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-100%
10Y return CAGR	-83.11%
10Y total return	-100%
150-day SMA	$11.59
1D price change	-0.74%
1M price change	-45.74%
1M total return	-45.74%
1W price change	-1.47%
1W total return	-1.47%
1Y price change	-73.71%
1Y return CAGR	-73.73%
1Y total return	-73.71%
20-day SMA	$6.55
200-day SMA	$12.58
3M price change	-48.41%
3M total return	-48.41%
3Y price change	-99.7%
3Y return CAGR	-85.49%
3Y total return	-99.7%
50-day SMA	$9.83
50-day SMA vs 200-day SMA	50under200
52-week high	$20.56
52-week high date	2025-12-12
52-week low	$5.01
52-week low date	2026-10-23
5Y price change	-100%
5Y return CAGR	-89.12%
5Y total return	-100%
6M price change	-58.33%
6M total return	-58.33%
All-time high	$20,600,000,000.00
All-time high date	2012-02-08
All-time low	$5.01
All-time low date	2026-10-23
Average true range (ATR)	$0.51
Average volume	1.1M
Beta (1Y)	1.29
Beta (2Y)	1.5
Beta (5Y)	1.79
Change from 52-week high	-73.98%
Change from 52-week low	6.79%
Change from all-time high	-100%
Change from all-time low	6.79%
Change from open	0.94%
Day's gap	-1.67%
Dollar volume	$2.6M
High price	$5.37
Low price	$5.10
Monthly RSI	29.83
Open price	$5.30
Position in 52-week range	92.59%
Premarket change	0.19%
Premarket close	$5.39
Premarket price	$5.40
Previous close	$5.39
Price vs 150-day SMA	-53.85%
Price vs 20-day SMA	-18.28%
Price vs 200-day SMA	-57.48%
Price vs 50-day SMA	-45.56%
Relative volume	0.46
RSI	18.95
Sharpe ratio	-1.57
Sharpe ratio (3Y)	-0.59
Sharpe ratio (5Y)	-1.01
Sortino ratio	-2.1
Sortino ratio (3Y)	-0.86
Sortino ratio (5Y)	-1.45
Volume	487.9K
Weekly RSI	29.41
YTD price change	-65.75%
YTD total return	-65.75%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14.1M
Float percentage	82.31%
Shares change (QoQ)	21.36%
Shares change (YoY)	216.89%
Shares held by insiders	0.24%
Shares held by institutions	39.36%
Shares outstanding	17.2M
Short % of float	20.81%
Short % of shares	17.13%
Short ratio	6.7 days

Deeper analysis on TNXP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TNXP report

Is a complete TNXP research report available?

No complete published report is available for Tonix Pharmaceuticals Holding Corp. (TNXP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Tonix Pharmaceuticals Holding Corp. (TNXP)

Price

Financial snapshot

Fair-value bridge

Latest news · TNXP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TNXP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TNXP

Frequently asked questions